Wet AMD- Pipeline Insight, 2018

"Wet AMD- Pipeline Insight, 2018" report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Wet AMD. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 75+ products along with 65+ companies involved.
Products covered by Phase
• Phase III, Phase II and Phase I
• Pre-clinical and Discovery
• Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Wet AMD
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Wet AMD
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report
• Provides an overview of therapeutic pipeline activity for Wet AMD across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Wet AMD therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Wet AMD

Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Wet AMD to formulate effective R&D strategies
• Assess challenges and opportunities that influence Wet AMD R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Wet AMD to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Overview
Age-Related Macular Degeneration
Risk factors for AMD
Wet AMD - Pathogenesis
Wet AMD – Clinical Features & Diagnosis
Wet AMD – Treatment Options
Pipeline Therapeutics (Active Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Abicipar: Allergan
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical & Discovery Stage Products
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Appendix

List of Figures, Tables and Charts Available in Wet AMD- Pipeline Insight, 2018

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products


Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

Keyplayers in Wet AMD- Pipeline Insight, 2018

Aciont
Acucela
Adalta
Adverum Biotechnologies
Aerie Pharmaceuticals
Alimera sciences
Allegro Opthalmics
Allergan
Allergan
Altacor
Apexigen
Ascendis Pharma
Bayer
Benitech Biopharma
Biolight life sciences
BioMAS
Boehringer Ingelheim
Charlesson
Clanotech
Coherus Biosciences
CoMentis
Daiichi Sankyo
Exonate
Genera Corporation
GenVec
GlaxoSmithKline
GreyBug Vision
Healios
Hemera Biosciences
Iconic Therapeutics
Janssen
Jerini Opthalmic
Kalos therapeutics
Kodiac Sciences
Light Sciences
Lpath
MeiraGTx
Neurotech
Novartis
Occurx
Ocugen
Ocular Therapeutix
OHR Pharmaceutical
OliX Pharmaceuticals
Omeros
OPKO Health
Opthea
Opthotech Corporation
Oxford Biomedica
Paloma Pharmaceuticals
PanOptica
Pfizer
pSivida
Quark
Regeneron
REGENXBIO
Roche
RXI Pharmaceuticals
S & I Ophthalmic
Sanofi
Santen
Santen Pharmaceutical
SciFluor Life Sciences
ThromboGenics
Tyrogenex